Page last updated: 2024-08-07 20:37:35
Replicase polyprotein 1ab
[no definition available]
Synonyms
pp1ab;
ORF1ab polyprotein
Research
Bioassay Publications (49)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 49 (100.00) | 2.80 |
Compounds (292)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 4-hydroxybenzaldehyde | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.9900 | 1 | 1 |
| quinacrine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 50.0000 | 1 | 1 |
| taxifolin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 73.0000 | 1 | 1 |
| catechin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 100.0000 | 1 | 1 |
| sk&f-38393 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.8000 | 1 | 0 |
| 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 100.0000 | 1 | 1 |
| pyrithione | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0500 | 1 | 0 |
| 4,5,6,7-tetrabromo-2-azabenzimidazole | Severe acute respiratory syndrome coronavirus 2 | IC50 | 20.4900 | 1 | 1 |
| theophylline | Severe acute respiratory syndrome coronavirus 2 | IC50 | 100.0000 | 1 | 1 |
| amodiaquine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.1500 | 1 | 1 |
| benserazide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1400 | 1 | 0 |
| bronopol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.4100 | 2 | 1 |
| bronopol | Severe acute respiratory syndrome coronavirus 2 | Ki | 2.5000 | 1 | 1 |
| caffeine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 100.0000 | 1 | 1 |
| N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester | Severe acute respiratory syndrome coronavirus 2 | IC50 | 10.6900 | 1 | 1 |
| camostat | Severe acute respiratory syndrome coronavirus 2 | IC50 | 35.0000 | 2 | 2 |
| carmofur | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.5433 | 6 | 5 |
| chloroquine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 8.2500 | 2 | 3 |
| chloroxine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.2400 | 1 | 1 |
| chlorpromazine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 11.2400 | 1 | 2 |
| disulfiram | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.9171 | 9 | 8 |
| disulfiram | Severe acute respiratory syndrome coronavirus 2 | Ki | 3.7100 | 1 | 1 |
| ebastine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.9200 | 1 | 1 |
| ebselen | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.7928 | 13 | 13 |
| emodin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 10.0000 | 1 | 1 |
| fluphenazine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 11.8000 | 1 | 2 |
| hexachlorophene | Severe acute respiratory syndrome coronavirus 2 | IC50 | 14.4100 | 3 | 4 |
| hydroxychloroquine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3,584.0000 | 1 | 1 |
| 1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.5800 | 1 | 0 |
| 1-(2-naphthalenyl)-2-propen-1-one | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.2400 | 1 | 0 |
| nsc 664704 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.5000 | 1 | 1 |
| lansoprazole | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.9950 | 1 | 0 |
| beta-lapachone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 9.0900 | 3 | 3 |
| loperamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 9.2700 | 1 | 1 |
| mefloquine hydrochloride | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.3300 | 1 | 1 |
| vitamin k 3 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.9600 | 1 | 1 |
| mequitazine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.2800 | 1 | 1 |
| niclosamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 30.0933 | 3 | 3 |
| masoprocol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.5900 | 1 | 0 |
| perhexiline | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.3800 | 1 | 1 |
| phenazopyridine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 28.0000 | 1 | 1 |
| promethazine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 13.6450 | 1 | 2 |
| protoporphyrin ix | Severe acute respiratory syndrome coronavirus 2 | IC50 | 23.0000 | 1 | 1 |
| 3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one | Severe acute respiratory syndrome coronavirus 2 | IC50 | 21.5200 | 2 | 2 |
| alkannin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 15.7500 | 2 | 2 |
| thioridazine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.6900 | 1 | 1 |
| thiram | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0500 | 1 | 0 |
| tilorone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.0900 | 1 | 1 |
| triclosan | Severe acute respiratory syndrome coronavirus 2 | IC50 | 75.0000 | 1 | 1 |
| 17-alpha-hydroxyprogesterone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.3000 | 1 | 1 |
| triparanol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.0500 | 1 | 1 |
| acriflavine chloride | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.9800 | 1 | 0 |
| penicillin v | Severe acute respiratory syndrome coronavirus 2 | IC50 | 50.0000 | 1 | 1 |
| pyromellitic acid | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.7000 | 1 | 1 |
| proflavine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.1600 | 3 | 2 |
| thiohexam | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.7700 | 1 | 0 |
| tetramethylthiuram monosulfide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.9400 | 1 | 0 |
| chloranil | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.0600 | 2 | 1 |
| dibenzothiazyl disulfide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1600 | 1 | 0 |
| captan | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.6700 | 1 | 0 |
| apomorphine hydrochloride, anhydrous | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.5200 | 1 | 0 |
| plumbagin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 17.1000 | 1 | 1 |
| dithiol | Severe acute respiratory syndrome coronavirus 2 | Ki | 1.4000 | 1 | 1 |
| 4-hydroxyphenylethanol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.6800 | 1 | 1 |
| dihydroergotamine | Severe acute respiratory syndrome coronavirus 2 | Ki | 107.3600 | 1 | 1 |
| abietic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 189.1000 | 1 | 1 |
| 4-(dimethylamino)benzoic acid | Severe acute respiratory syndrome coronavirus 2 | Ki | 1.3800 | 1 | 1 |
| agaric acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 23.5400 | 2 | 2 |
| isobarbaloin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 16.7950 | 2 | 2 |
| phenethyl isothiocyanate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 10.1300 | 1 | 1 |
| oxyclozanide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.7100 | 1 | 1 |
| 1,2-benzisothiazoline-3-one | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.6600 | 1 | 1 |
| bonafton | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1000 | 1 | 0 |
| 4-biphenylylacetic acid ethyl ester | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2000 | 1 | 0 |
| benserazide hydrochloride | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1400 | 1 | 0 |
| razoxane | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.1900 | 1 | 0 |
| penfluridol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.0100 | 1 | 1 |
| carbidopa | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.5500 | 1 | 0 |
| exifone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.3800 | 1 | 0 |
| oltipraz | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.4150 | 1 | 0 |
| caracemide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.3300 | 1 | 0 |
| zinc ethylphenyldithiocarbamate | Severe acute respiratory syndrome coronavirus 2 | Ki | 1.0000 | 1 | 1 |
| nelfinavir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 41.5000 | 1 | 1 |
| baicalin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.4104 | 4 | 5 |
| epigallocatechin gallate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.1500 | 1 | 0 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | Severe acute respiratory syndrome coronavirus 2 | IC50 | 27.7700 | 1 | 1 |
| sinefungin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.3072 | 4 | 5 |
| vanitiolide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.9600 | 2 | 1 |
| carbobenzoxyvalylphenylalanine aldehyde | Severe acute respiratory syndrome coronavirus 2 | IC50 | 20.0000 | 1 | 1 |
| tetrandrine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.0000 | 1 | 1 |
| sennoside A | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.5900 | 1 | 0 |
| LSM-4272 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 9.9600 | 2 | 2 |
| pyrrolidine dithiocarbamic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2100 | 1 | 0 |
| calpeptin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 9.0476 | 6 | 8 |
| 6,6'-dithiodinicotinic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2400 | 1 | 0 |
| lopinavir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 14.9150 | 2 | 4 |
| lopinavir | Severe acute respiratory syndrome coronavirus 2 | Ki | 15.0000 | 1 | 1 |
| osajin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.8700 | 1 | 1 |
| zpck | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.3100 | 1 | 1 |
| tingenone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 9.9000 | 1 | 1 |
| tingenone | Severe acute respiratory syndrome coronavirus 2 | Ki | 4.0000 | 1 | 1 |
| tanshinone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 20.4550 | 2 | 2 |
| tanshinone | Severe acute respiratory syndrome coronavirus 2 | Ki | 13.7000 | 1 | 1 |
| celastrol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 10.3000 | 1 | 1 |
| celastrol | Severe acute respiratory syndrome coronavirus 2 | Ki | 4.2000 | 1 | 1 |
| omega-(4-iodophenyl)pentadecanoic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.2500 | 1 | 0 |
| sulbactam | Severe acute respiratory syndrome coronavirus 2 | IC50 | 50.0000 | 1 | 1 |
| 2,4,6-triiodoresorcinol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.3300 | 1 | 0 |
| moxifloxacin | Severe acute respiratory syndrome coronavirus 2 | Ki | 249.0000 | 1 | 1 |
| bazedoxifene | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.4400 | 1 | 1 |
| celastrol methyl ester | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.5000 | 1 | 1 |
| celastrol methyl ester | Severe acute respiratory syndrome coronavirus 2 | Ki | 3.1000 | 1 | 1 |
| miltirone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 21.1000 | 1 | 1 |
| aloesin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 38.9000 | 1 | 1 |
| cryptotanshinone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 59.4665 | 4 | 4 |
| cryptotanshinone | Severe acute respiratory syndrome coronavirus 2 | Ki | 9.0000 | 1 | 1 |
| ampelopsin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1800 | 1 | 0 |
| tanshinone ii a | Severe acute respiratory syndrome coronavirus 2 | IC50 | 30.4903 | 3 | 3 |
| 2-phenyl-1,2-benzisothiazol-3-(2h)-one | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.4900 | 1 | 1 |
| anidulafungin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.6400 | 1 | 1 |
| anacardic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 8.9200 | 2 | 2 |
| pectolinarin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 38.0000 | 1 | 1 |
| carboxyebselen | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1300 | 1 | 1 |
| n(4)-hydroxycytidine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1567 | 2 | 3 |
| dronedarone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.9200 | 1 | 1 |
| darunavir | Severe acute respiratory syndrome coronavirus 2 | Ki | 518.0000 | 1 | 1 |
| 1-methylpropyl-2-imidazolyl disulfide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 18.2414 | 6 | 6 |
| nsc 95397 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 17.9300 | 2 | 2 |
| withaferin a | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.5850 | 2 | 2 |
| berbamine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.8700 | 1 | 1 |
| methyl 3,4-dihydroxybenzoate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.7600 | 1 | 1 |
| nsc228155 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1000 | 1 | 0 |
| nsc 663284 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.6300 | 2 | 2 |
| ritonavir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 20.0000 | 1 | 1 |
| 5-amino-8-hydroxyquinoline | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.0500 | 1 | 0 |
| ouabain | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0970 | 1 | 1 |
| tosylphenylalanyl chloromethyl ketone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.3700 | 1 | 0 |
| digitoxin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2300 | 1 | 1 |
| silver sulfadiazine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.7500 | 1 | 0 |
| abacavir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 18.6250 | 1 | 2 |
| delavirdine mesylate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.9900 | 1 | 0 |
| ferruginol | Severe acute respiratory syndrome coronavirus 2 | IC50 | 49.6000 | 1 | 2 |
| isopimaric acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 283.5000 | 1 | 2 |
| hematoxylin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2200 | 1 | 0 |
| acetylleucyl-leucyl-norleucinal | Severe acute respiratory syndrome coronavirus 2 | IC50 | 8.5967 | 2 | 3 |
| gw 3965 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 21.5200 | 2 | 3 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.1874 | 6 | 8 |
| tenofovir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 12.9850 | 1 | 2 |
| shikonin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 15.7449 | 2 | 2 |
| 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.3900 | 1 | 1 |
| 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2617 | 2 | 3 |
| 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.1200 | 1 | 1 |
| IPA-3 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.4300 | 2 | 1 |
| tenatoprazole | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.9700 | 1 | 0 |
| hirsutanone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.1000 | 2 | 2 |
| lanatoside c | Severe acute respiratory syndrome coronavirus 2 | IC50 | 50.0000 | 1 | 1 |
| N-[2-[5-[(2,4-dichlorophenyl)methylsulfonyl]-1,3,4-oxadiazol-2-yl]ethyl]carbamic acid tert-butyl ester | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.2200 | 1 | 0 |
| sch-202676 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.9800 | 1 | 0 |
| 1-phenyl-5-mercaptotetrazole | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.3600 | 1 | 0 |
| 1-(4-Methoxyphenyl)-2-nitroethylene | Severe acute respiratory syndrome coronavirus 2 | IC50 | 47.5000 | 1 | 1 |
| captax | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.7400 | 1 | 0 |
| curcumin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 31.7500 | 1 | 2 |
| 3-chloro-1-(3,4-dichlorophenyl)-4-(4-morpholinyl)-1h-pyrrole-2,5-dione | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.8350 | 1 | 0 |
| zuclomiphene | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.3600 | 1 | 1 |
| chlorogenic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 39.4800 | 1 | 1 |
| thioguanine anhydrous | Severe acute respiratory syndrome coronavirus 2 | IC50 | 18.4000 | 4 | 4 |
| succimer | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.7200 | 1 | 0 |
| digoxin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1900 | 1 | 1 |
| 4,5,6,7-tetrachloroindan-1,3-dione | Severe acute respiratory syndrome coronavirus 2 | IC50 | 138.0000 | 1 | 1 |
| ccg 50014 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1900 | 1 | 0 |
| bi-78d3 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.3000 | 1 | 0 |
| ssya10-001 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.5230 | 2 | 2 |
| pr-619 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.4100 | 1 | 0 |
| 5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.0000 | 2 | 2 |
| S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.0000 | 2 | 2 |
| 1-(3,5-dimethylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.1700 | 1 | 0 |
| toremifene | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.5800 | 1 | 1 |
| telaprevir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 11.6380 | 5 | 5 |
| droloxifene | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.6000 | 1 | 1 |
| salinomycin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.2400 | 1 | 1 |
| N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 12.8000 | 2 | 3 |
| 8-(Trifluoromethyl)-9H-purin-6-amine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 13.9000 | 1 | 1 |
| l 663536 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 21.5200 | 2 | 2 |
| ro 106-9920 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.1200 | 1 | 0 |
| suramin sodium | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.5000 | 2 | 2 |
| 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.1450 | 2 | 1 |
| sitagliptin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 16.1400 | 1 | 1 |
| alsterpaullone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.5000 | 1 | 1 |
| ginkgetin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 32.0000 | 1 | 1 |
| ginkgetin | Severe acute respiratory syndrome coronavirus 2 | Ki | 30.2000 | 1 | 1 |
| quercetin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 23.8000 | 1 | 1 |
| quercetin | Severe acute respiratory syndrome coronavirus 2 | Ki | 7.4000 | 1 | 1 |
| apigenin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 141.9100 | 2 | 1 |
| luteolin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 20.0000 | 1 | 1 |
| herbacetin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 33.0000 | 1 | 1 |
| amentoflavone | Severe acute respiratory syndrome coronavirus 2 | IC50 | 8.3000 | 2 | 2 |
| amentoflavone | Severe acute respiratory syndrome coronavirus 2 | Ki | 13.8000 | 1 | 1 |
| baicalein | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.2200 | 9 | 9 |
| hyperoside | Severe acute respiratory syndrome coronavirus 2 | IC50 | 50.5000 | 1 | 1 |
| myricetin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.3100 | 1 | 0 |
| sciadopitysin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 38.4000 | 1 | 1 |
| sciadopitysin | Severe acute respiratory syndrome coronavirus 2 | Ki | 35.6000 | 1 | 1 |
| scutellarein | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.0200 | 1 | 1 |
| rosmarinic acid | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.8600 | 1 | 0 |
| acteoside | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.5400 | 1 | 0 |
| savinin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 25.0000 | 1 | 1 |
| rhoifolin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 27.0000 | 1 | 1 |
| cyclosporine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.8200 | 1 | 1 |
| proscillaridin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.0400 | 1 | 1 |
| benzyloxycarbonyl-phe-ala-fluormethylketone | Severe acute respiratory syndrome coronavirus 2 | Ki | 64.0000 | 1 | 1 |
| bilobetin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 72.3000 | 1 | 1 |
| andrographolide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 15.0000 | 1 | 1 |
| bay 11-7082 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.8200 | 1 | 0 |
| bay 11-7085 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.8400 | 1 | 0 |
| indinavir sulfate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 22.5300 | 1 | 2 |
| bedaquiline | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.3600 | 1 | 0 |
| cinanserin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 84.9853 | 3 | 3 |
| ildamen | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.3500 | 1 | 0 |
| N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 67.0000 | 2 | 2 |
| N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide | Severe acute respiratory syndrome coronavirus 2 | Ki | 6.6333 | 2 | 3 |
| broussochalcone a | Severe acute respiratory syndrome coronavirus 2 | IC50 | 25.6500 | 1 | 2 |
| rupintrivir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 215.0000 | 3 | 4 |
| rupintrivir | Severe acute respiratory syndrome coronavirus 2 | Ki | 10.0000 | 1 | 2 |
| Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | Severe acute respiratory syndrome coronavirus 2 | Ki | 2.2600 | 2 | 2 |
| mdl 201053 | Severe acute respiratory syndrome coronavirus 2 | Ki | 25.7000 | 1 | 1 |
| ciclesonide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 4.3300 | 1 | 1 |
| 5-Chloro-3-pyridinyl 2-furoate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0600 | 2 | 2 |
| proflavine hemisulfate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.8300 | 1 | 0 |
| carbobenzoxy-leucyl-leucyl-norvalinal | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.4268 | 5 | 6 |
| sja 6017 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 20.0000 | 1 | 1 |
| sp 100030 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 28.8500 | 2 | 2 |
| perampanel | Severe acute respiratory syndrome coronavirus 2 | IC50 | 175.0000 | 1 | 1 |
| gw0742 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 22.2700 | 2 | 2 |
| benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal | Severe acute respiratory syndrome coronavirus 2 | IC50 | 10.3800 | 1 | 1 |
| masitinib | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.5000 | 1 | 1 |
| sepantronium | Severe acute respiratory syndrome coronavirus 2 | IC50 | 13.6000 | 2 | 2 |
| n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.8067 | 10 | 12 |
| triptohypol C | Severe acute respiratory syndrome coronavirus 2 | IC50 | 21.7000 | 1 | 1 |
| ym 155 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.4700 | 1 | 1 |
| 2-(4-chlorophenyl)-1,2-benzothiazol-3-one | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.3900 | 1 | 1 |
| np 031112 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.0865 | 8 | 7 |
| compound 26 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.0700 | 1 | 0 |
| Dihydrotanshinone I | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.4950 | 2 | 2 |
| Dihydrotanshinone I | Severe acute respiratory syndrome coronavirus 2 | Ki | 11.2000 | 1 | 1 |
| PF-00835231 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1364 | 9 | 11 |
| PF-00835231 | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.0009 | 1 | 12 |
| mk-0893 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 24.3300 | 1 | 1 |
| 5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-amine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0300 | 1 | 0 |
| narlaprevir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.7290 | 1 | 2 |
| alloin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 14.4200 | 2 | 2 |
| rabeprazole sodium | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.7400 | 1 | 0 |
| Benzotriazol-1-yl 1H-indole-5-carboxylate | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.0075 | 2 | 2 |
| tannins | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.1000 | 1 | 1 |
| tannins | Severe acute respiratory syndrome coronavirus 2 | Ki | 1.4000 | 1 | 1 |
| oritavancin | Severe acute respiratory syndrome coronavirus 2 | IC50 | 24.1500 | 1 | 1 |
| 5-Bromopyridin-3-yl furan-2-carboxylate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0500 | 1 | 1 |
| 5-Chloropyridin-3-yl 5-(4-chlorophenyl)furan-2-carboxylate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0630 | 1 | 1 |
| (5-Chloropyridin-3-yl) 1H-indole-5-carboxylate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.8500 | 3 | 3 |
| 5-Chloropyridin-3-yl 1H-indole-2-carboxylate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0517 | 2 | 3 |
| vx-770 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.5700 | 1 | 1 |
| phenylmercuric acetate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.4000 | 1 | 1 |
| phenylmercuric acetate | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.4050 | 1 | 2 |
| thimerosal | Severe acute respiratory syndrome coronavirus 2 | Ki | 2.4000 | 1 | 1 |
| 2,3,4,10-tetrahydro-7,10-dimethyl-2,4-dioxobenzo(g)pteridine | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.5300 | 1 | 1 |
| tanshinone ii a sodium sulfonate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.6500 | 1 | 1 |
| GRL-0617 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.1191 | 12 | 12 |
| (5-Chloropyridin-3-yl) 1H-indole-4-carboxylate | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1872 | 4 | 5 |
| KOM70144 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.5200 | 3 | 3 |
| 2-(3-oxo-1,2-benzothiazol-2-yl)-N-phenylacetamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1652 | 1 | 1 |
| Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate | Severe acute respiratory syndrome coronavirus 2 | Ki | 2.2000 | 1 | 1 |
| abemaciclib | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.6200 | 1 | 1 |
| amg-837 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 24.1500 | 1 | 1 |
| N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.6000 | 2 | 3 |
| gilteritinib | Severe acute respiratory syndrome coronavirus 2 | IC50 | 6.7600 | 1 | 1 |
| lusutrombopag | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.7800 | 1 | 1 |
| ceritinib | Severe acute respiratory syndrome coronavirus 2 | IC50 | 2.8600 | 1 | 1 |
| osimertinib | Severe acute respiratory syndrome coronavirus 2 | IC50 | 3.2600 | 1 | 1 |
| 1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.3000 | 1 | 1 |
| bictegravir | Severe acute respiratory syndrome coronavirus 2 | Ki | 302.0000 | 1 | 1 |
| s 8932 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.1020 | 4 | 5 |
| sildenafil | Severe acute respiratory syndrome coronavirus 2 | IC50 | 10.3535 | 1 | 2 |
| amg531 | Severe acute respiratory syndrome coronavirus 2 | IC50 | 17.1033 | 3 | 3 |
| N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0726 | 11 | 13 |
| N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.0300 | 1 | 1 |
| 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.1184 | 10 | 10 |
| nirmatrelvir | Severe acute respiratory syndrome coronavirus 2 | IC50 | 0.0471 | 7 | 7 |
| nirmatrelvir | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.0031 | 5 | 5 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 4,5,6,7-tetrabromo-2-azabenzimidazole | Severe acute respiratory syndrome coronavirus 2 | EC50 | 14.1300 | 1 | 1 |
| amodiaquine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 3.1933 | 1 | 3 |
| astemizole | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.2350 | 1 | 2 |
| camostat | Severe acute respiratory syndrome coronavirus 2 | EC50 | 6.6703 | 2 | 3 |
| carmofur | Severe acute respiratory syndrome coronavirus 2 | EC50 | 24.3000 | 1 | 2 |
| chloroquine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.3333 | 1 | 6 |
| chloroxine | Severe acute respiratory syndrome coronavirus 2 | Kd | 4.6000 | 1 | 1 |
| chlorpromazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 7.7360 | 1 | 5 |
| clomipramine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 11.2800 | 1 | 2 |
| ebselen | Severe acute respiratory syndrome coronavirus 2 | EC50 | 4.6700 | 2 | 2 |
| emodin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 200.0000 | 1 | 2 |
| fluphenazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 16.2400 | 1 | 3 |
| fluspirilene | Severe acute respiratory syndrome coronavirus 2 | EC50 | 6.7150 | 1 | 2 |
| hexachlorophene | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.7900 | 1 | 1 |
| hydroxychloroquine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.6567 | 1 | 3 |
| hydroxyzine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 14.4000 | 1 | 1 |
| loperamide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.0800 | 1 | 5 |
| mefloquine hydrochloride | Severe acute respiratory syndrome coronavirus 2 | EC50 | 11.4800 | 1 | 2 |
| promethazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 9.6700 | 1 | 2 |
| 3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one | Severe acute respiratory syndrome coronavirus 2 | EC50 | 11.2200 | 1 | 1 |
| alkannin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 4.6700 | 1 | 1 |
| imatinib | Severe acute respiratory syndrome coronavirus 2 | EC50 | 12.5000 | 1 | 3 |
| thiethylperazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 7.8600 | 1 | 1 |
| triflupromazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 6.0700 | 1 | 2 |
| cycloheximide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.1145 | 1 | 2 |
| chlorphenoxamine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 16.3350 | 1 | 2 |
| triparanol | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.2800 | 1 | 1 |
| emetine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.0325 | 1 | 2 |
| acetophenazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 23.6000 | 1 | 1 |
| ribavirin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 109.5000 | 1 | 1 |
| gemcitabine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 3.0800 | 1 | 2 |
| baicalin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 10.2700 | 1 | 1 |
| baicalin | Severe acute respiratory syndrome coronavirus 2 | Kd | 11.9500 | 2 | 2 |
| methotrimeprazine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 2.5000 | 1 | 1 |
| lopinavir | Severe acute respiratory syndrome coronavirus 2 | EC50 | 12.8200 | 1 | 5 |
| anacardic acid | Severe acute respiratory syndrome coronavirus 2 | EC50 | 3.9800 | 1 | 1 |
| nutlin 3 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 36.9000 | 1 | 1 |
| anisomycin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.0965 | 1 | 2 |
| homoharringtonine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.0710 | 1 | 1 |
| nsc 663284 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 4.4700 | 2 | 2 |
| terconazole | Severe acute respiratory syndrome coronavirus 2 | EC50 | 13.7600 | 1 | 2 |
| gw 3965 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 3.5500 | 1 | 1 |
| thiothixene | Severe acute respiratory syndrome coronavirus 2 | EC50 | 7.3000 | 1 | 2 |
| curcumin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 10.0000 | 1 | 1 |
| benztropine | Severe acute respiratory syndrome coronavirus 2 | EC50 | 19.1150 | 1 | 2 |
| tamoxifen | Severe acute respiratory syndrome coronavirus 2 | EC50 | 51.4950 | 1 | 2 |
| toremifene | Severe acute respiratory syndrome coronavirus 2 | EC50 | 12.4350 | 1 | 2 |
| dasatinib | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.0325 | 1 | 2 |
| l 663536 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 11.2200 | 1 | 1 |
| quercetin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 83.4000 | 1 | 1 |
| luteolin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 10.6000 | 1 | 1 |
| baicalein | Severe acute respiratory syndrome coronavirus 2 | EC50 | 2.3150 | 2 | 2 |
| baicalein | Severe acute respiratory syndrome coronavirus 2 | Kd | 18.4000 | 3 | 3 |
| dothiepin hydrochloride | Severe acute respiratory syndrome coronavirus 2 | EC50 | 3.4000 | 1 | 1 |
| N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 16.7700 | 1 | 1 |
| sotrastaurin | Severe acute respiratory syndrome coronavirus 2 | EC50 | 9.7000 | 1 | 1 |
| saracatinib | Severe acute respiratory syndrome coronavirus 2 | EC50 | 2.9000 | 1 | 1 |
| n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.6550 | 2 | 2 |
| (5-Chloropyridin-3-yl) 1H-indole-5-carboxylate | Severe acute respiratory syndrome coronavirus 2 | EC50 | 33.8500 | 2 | 2 |
| tanshinone ii a sodium sulfonate | Severe acute respiratory syndrome coronavirus 2 | Kd | 61.0000 | 1 | 1 |
| GRL-0617 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 27.6000 | 1 | 1 |
| GRL-0617 | Severe acute respiratory syndrome coronavirus 2 | Kd | 6.7450 | 2 | 2 |
| (5-Chloropyridin-3-yl) 1H-indole-4-carboxylate | Severe acute respiratory syndrome coronavirus 2 | EC50 | 5.5333 | 3 | 3 |
| KOM70144 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 21.0000 | 1 | 1 |
| N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 12.9000 | 1 | 1 |
| s 8932 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.7100 | 3 | 3 |
| amg531 | Severe acute respiratory syndrome coronavirus 2 | EC50 | 8.9100 | 1 | 1 |
| N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.5500 | 3 | 4 |
| molnupiravir | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.1540 | 1 | 1 |
| 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide | Severe acute respiratory syndrome coronavirus 2 | EC50 | 0.5250 | 2 | 2 |
| nirmatrelvir | Severe acute respiratory syndrome coronavirus 2 | EC50 | 3.4000 | 1 | 1 |
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.Nature, , Volume: 605, Issue:7909, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy, , 06-23, Volume: 64, Issue:7, 2020
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure of MNature, , Volume: 582, Issue:7811, 2020
[no title available],
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLEuropean journal of medicinal chemistry, , Jan-15, Volume: 228, 2022
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure of MNature, , Volume: 582, Issue:7811, 2020
[no title available],
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure of MNature, , Volume: 582, Issue:7811, 2020
[no title available],
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy, , 06-23, Volume: 64, Issue:7, 2020
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.bioRxiv : the preprint server for biology, , Aug-11, 2020
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.bioRxiv : the preprint server for biology, , Aug-11, 2020
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy, , 06-23, Volume: 64, Issue:7, 2020
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
[no title available]ACS medicinal chemistry letters, , Sep-08, Volume: 13, Issue:9, 2022
Potent Inhibition of SARS-CoV-2 nsp14 Journal of medicinal chemistry, , 04-28, Volume: 65, Issue:8, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy, , 06-23, Volume: 64, Issue:7, 2020
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.Journal of natural products, , 01-22, Volume: 84, Issue:1, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure of MNature, , Volume: 582, Issue:7811, 2020
[no title available],
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2.Journal of natural products, , 02-25, Volume: 85, Issue:2, 2022
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
[no title available],
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Structure of MNature, , Volume: 582, Issue:7811, 2020
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
[no title available]European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 72, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.Bioorganic & medicinal chemistry, , 01-01, Volume: 29, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure of MNature, , Volume: 582, Issue:7811, 2020
[no title available],
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.Journal of medicinal chemistry, , 10-27, Volume: 65, Issue:20, 2022
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.Journal of medicinal chemistry, , 10-13, Volume: 65, Issue:19, 2022
A Patent Review on SARS Coronavirus Main Protease (3CLChemMedChem, , 01-05, Volume: 17, Issue:1, 2022
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.RSC medicinal chemistry, , Oct-20, Volume: 12, Issue:10, 2021
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.Journal of the American Chemical Society, , 12-15, Volume: 143, Issue:49, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
[no title available]bioRxiv : the preprint server for biology, , Feb-12, 2021
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.ACS infectious diseases, , 08-14, Volume: 6, Issue:8, 2020
[no title available]Journal of medicinal chemistry, , 07-14, Volume: 65, Issue:13, 2022
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.Journal of medicinal chemistry, , 10-14, Volume: 64, Issue:19, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.ACS infectious diseases, , 08-14, Volume: 6, Issue:8, 2020
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.ACS medicinal chemistry letters, , Aug-12, Volume: 12, Issue:8, 2021
Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.European journal of medicinal chemistry, , Nov-05, Volume: 223, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy, , 06-23, Volume: 64, Issue:7, 2020
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy, , 06-23, Volume: 64, Issue:7, 2020
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.bioRxiv : the preprint server for biology, , Aug-11, 2020
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
[no title available]ChemMedChem, , 03-18, Volume: 16, Issue:6, 2021
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.Journal of the American Chemical Society, , 12-15, Volume: 143, Issue:49, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.Science (New York, N.Y.), , 06-19, Volume: 368, Issue:6497, 2020
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Perspectives on SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 48, 2021
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews, , Volume: 41, Issue:1, 2021
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.Science (New York, N.Y.), , 06-19, Volume: 368, Issue:6497, 2020
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.ACS medicinal chemistry letters, , Aug-11, Volume: 13, Issue:8, 2022
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.European journal of medicinal chemistry, , Mar-05, Volume: 231, 2022
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.Bioorganic & medicinal chemistry letters, , 04-15, Volume: 62, 2022
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.Journal of medicinal chemistry, , 07-14, Volume: 65, Issue:13, 2022
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.Journal of medicinal chemistry, , 10-27, Volume: 65, Issue:20, 2022
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.Journal of medicinal chemistry, , 10-13, Volume: 65, Issue:19, 2022